Shire to Appeal Verdict on Zydus Colitis Drug

Sep 20, 2016

in-Pharma Technologist

Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine), according to an in-Pharma Technologist article.

The court ruled that a proposed generic of Lialda from Zydus Pharmaceuticals did not infringe on U.S. Patent No. 6,773,720. The story said this was one of four patents on Lialda that was scheduled to expire in June 2020.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments